Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab and Apatinib as Neoadjuvant Therapy for Rectal Cancer
NCT07687433Phase 2Active, not recruiting
- Sponsor
- Harbin Medical University
- Start
- May 2026
- Primary completion
- May 2028
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab, Rivoceranib in rectal cancer, sponsored by Harbin Medical University. Started May 2026; status: active, not recruiting.
02
Drugs
adebrelimabRivoceranib
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT07687433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07687433.